RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases – results and lessons learnt

BACKGROUND: Brain metastases occur in up to 75% of patients with advanced melanoma. Most are treated with whole-brain radiotherapy (WBRT), with limited effectiveness. Vandetanib, an inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor and rearranged during trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Avinash, Roberts, Corran, Tysoe, Finn, Goff, Matthew, Nobes, Jenny, Lester, James, Marshall, Ernie, Corner, Carie, Wolstenholme, Virginia, Kelly, Charles, Wise, Adelyn, Collins, Linda, Love, Sharon, Woodward, Martha, Salisbury, Amanda, Middleton, Mark R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104891/
https://www.ncbi.nlm.nih.gov/pubmed/27711083
http://dx.doi.org/10.1038/bjc.2016.318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104891/
https://www.ncbi.nlm.nih.gov/pubmed/27711083
http://dx.doi.org/10.1038/bjc.2016.318

Ejemplares similares